https://www.selleckchem.com/products/tno155.html
Survival among patients diagnosed with acute promyelocytic leukemia (APL) has significantly improved with the use of all-trans retinoic acid and arsenic trioxide. However, the need for immediate diagnosis and access to specialized care and the cost associated with APL management can potentially act as barriers for disadvantaged patients. The influence of sociodemographic factors on the outcomes of patients with APL remains unclear. The authors used the National Cancer Institute's Surveillance, Epidemiology, and End Results program to cha
Like
Comment
Share
